ANGPTL3 Blocker Halves LDL in High-Risk Group

(MedPage Today) -- Patients with refractory familial hypercholesterolemia that cannot be controlled with statins and PCSK9 inhibitors appeared to respond to evinacumab, a novel, fully human monoclonal antibody that inhibits angiopoietin-like 3...